Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 86

1.

Outcome reporting in industry-sponsored trials of gabapentin for off-label use.

Vedula SS, Bero L, Scherer RW, Dickersin K.

N Engl J Med. 2009 Nov 12;361(20):1963-71. doi: 10.1056/NEJMsa0906126.

2.

Implementation of a publication strategy in the context of reporting biases. A case study based on new documents from Neurontin litigation.

Vedula SS, Goldman PS, Rona IJ, Greene TM, Dickersin K.

Trials. 2012 Aug 13;13:136. doi: 10.1186/1745-6215-13-136.

3.
4.

Diabetic peripheral neuropathic pain: is gabapentin effective?

Hyatt JD, Daniel D, Tran QV, Millares M, Kubota DR.

Am Fam Physician. 2011 Sep 1;84(5):480, 482; author reply 482. No abstract available.

5.

Reporting of trials of gabapentin.

Gordh TE, Jensen TS, Kalso E.

N Engl J Med. 2010 Apr 29;362(17):1641; author reply 1641-2. doi: 10.1056/NEJMc1000964. No abstract available.

6.

Apparent discrepancy between published study of gabapentin treatment and internal company report.

Mayo-Wilson E.

J Clin Psychiatry. 2013 Aug;74(8):853-4. doi: 10.4088/JCP.13lr08420. No abstract available.

PMID:
24021509
7.

Off-label prescribing explained. Why your doctor may recommend meds that aren't FDA-approved for your condition.

[No authors listed]

Johns Hopkins Med Lett Health After 50. 2011 Jun;23(4):7. No abstract available.

PMID:
21702115
8.

Examination of the evidence for off-label use of gabapentin.

Mack A.

J Manag Care Pharm. 2003 Nov-Dec;9(6):559-68. Review.

9.

Efficacy of gabapentin for treatment of adults with phantom limb pain.

Abbass K.

Ann Pharmacother. 2012 Dec;46(12):1707-11. doi: 10.1345/aph.1Q793. Epub 2012 Dec 11. Review.

PMID:
23232019
10.

Compromising the medical literature: the hidden influence of industry-biased articles.

Fugh-Berman A, Siwek J.

Am Fam Physician. 2011 Sep 1;84(5):489-90. No abstract available.

11.

Intended and unintended consequences of the gabapentin off-label marketing lawsuit among patients with bipolar disorder.

Chace MJ, Zhang F, Fullerton CA, Huskamp HA, Gilden D, Soumerai SB.

J Clin Psychiatry. 2012 Nov;73(11):1388-94. doi: 10.4088/JCP.12m07794. Epub 2012 Oct 16.

PMID:
23146199
12.

Effectiveness of antiepileptic drugs for the treatment of bipolar disorder: findings from a systematic review.

Melvin CL, Carey TS, Goodman F, Oldham JM, Williams JW Jr, Ranney LM.

J Psychiatr Pract. 2008 Mar;14 Suppl 1:9-14. doi: 10.1097/01.pra.0000333583.75741.8b. Review. Erratum in: J Psychiatr Pract. 2008 May;14(3):193.

PMID:
19034205
13.

How reviews covered the unfolding scientific story of gabapentin for bipolar disorder.

Williams JW Jr, Ranney L, Morgan LC, Whitener L.

Gen Hosp Psychiatry. 2009 May-Jun;31(3):279-87. doi: 10.1016/j.genhosppsych.2009.02.006. Epub 2009 Apr 5. Review.

PMID:
19410108
14.

Gabapentin in the treatment of mental illness: the echo chamber of the case series.

Carey TS, Williams JW Jr, Oldham JM, Goodman F, Ranney LM, Whitener L, Morgan LC, Melvin CL.

J Psychiatr Pract. 2008 Mar;14 Suppl 1:15-27. doi: 10.1097/01.pra.0000333584.75741.45. Review. Erratum in: J Psychiatr Pract. 2008 May;14(3):193.

PMID:
19034206
15.

Narrative review: the promotion of gabapentin: an analysis of internal industry documents.

Steinman MA, Bero LA, Chren MM, Landefeld CS.

Ann Intern Med. 2006 Aug 15;145(4):284-93. Review.

PMID:
16908919
16.

Evidence, regulation and 'rational' prescribing: the case of gabapentin for neuropathic pain.

Ghinea N, Lipworth W, Kerridge I.

J Eval Clin Pract. 2015 Feb;21(1):28-33. doi: 10.1111/jep.12223. Epub 2014 Jul 2.

PMID:
24986307
17.

Association of trial registration with the results and conclusions of published trials of new oncology drugs.

Rasmussen N, Lee K, Bero L.

Trials. 2009 Dec 16;10:116. doi: 10.1186/1745-6215-10-116.

18.

Empirical evidence for selective reporting of outcomes in randomized trials: comparison of protocols to published articles.

Chan AW, Hróbjartsson A, Haahr MT, Gøtzsche PC, Altman DG.

JAMA. 2004 May 26;291(20):2457-65.

PMID:
15161896
19.

[Selective reporting of positive outcomes in randomised trials--secondary publication.. A comparison of protocols with published reports].

Hróbjartsson A, Chan AW, Haahr MT, Gøtzsche PC, Altman DG.

Ugeskr Laeger. 2005 Aug 22;167(34):3189-91. Danish.

PMID:
16117920
20.

Pregabalin: new drug. Very similar to gabapentin.

[No authors listed]

Prescrire Int. 2005 Dec;14(80):203-6.

PMID:
16397976
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk